Live Analyst Rating Changes 25944 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Alex Thompson CFA
STIF

Alex Thompson CFA

Stifel Nicolaus
Wall Street Analyst
★★★★☆
#575
on 13Foresight · ranked by our own returns
71%
Success Rate
+12.0%
Average Return
39 of 55 calls profitable · +37.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 71% of Alex Thompson CFA's ratings turned a profit when each position was held for 1 year — averaging +12.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

90 Buy 15 Hold 0 Sell
Alex's Stock Coverage 26 ratings · 2026-08-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SEPN
Septerna, Inc.
 Aug 16, 2026 BUY Strong Buy
+15.7% avg upside
12 analysts
$46.00
5.03% Upside
 -0.6% ·
ALMS
Alumis Inc.
 Aug 13, 2026 BUY Strong Buy
+54.2% avg upside
11 analysts
$44.00
76.94% Upside
 -0.1% ·
JBIO
Jade Biosciences
 Aug 13, 2026 BUY Strong Buy
+143.2% avg upside
16 analysts
$40.00
66.68% Upside
 +3.8% ·
CGEM
Cullinan Management
 Aug 13, 2026 BUY Strong Buy
+64.4% avg upside
15 analysts
$28.00
34.43% Upside
 +3.6% ·
KYMR
Kymera Therapeutics
 Aug 13, 2026 BUY Strong Buy
-13.0% avg upside
37 analysts
$132.00
5.63% Upside
 +6.1% ·
DNTH
Dianthus Therapeutics
 Aug 13, 2026 BUY Strong Buy
-14.9% avg upside
29 analysts
$133.00
13.25% Upside
 +5.4% ·
VRDN
Viridian Therapeutics
 Aug 13, 2026 BUY Strong Buy
+47.6% avg upside
32 analysts
$40.00
63.93% Upside
 +0.4% ·
SYRE
Spyre Therapeutics
 Aug 13, 2026 BUY Strong Buy
-10.9% avg upside
23 analysts
$123.00
12.66% Upside
 +1.8% ·
EVMN
Evommune, Inc.
 Aug 11, 2026 BUY Strong Buy
+148.1% avg upside
12 analysts
$30.00
101.30% Upside
 +3.8% ·
IMVT
Immunovant
 Aug 11, 2026 BUY Strong Buy
-9.0% avg upside
24 analysts
$57.00
25.96% Upside
 +5.5% ·
TVTX
Travere Therapeutics
 Aug 09, 2026 HOLD Strong Buy
-10.0% avg upside
22 analysts
$62.00
3.75% Downside
 +4.3% ·
ARGX
Argenx Se
 Jul 28, 2026 BUY Strong Buy
-17.8% avg upside
47 analysts
$1282.00
26.51% Upside
 +13.2% ·
CLDX
Celldex
 Jul 22, 2026 BUY Strong Buy
-2.1% avg upside
28 analysts
$68.00
62.71% Upside
 +20.6% ·
CRNX
Crinetics Pharmaceuticals
 Jul 08, 2026 HOLD Buy
-8.5% avg upside
21 analysts
$85.00
0.46% Upside
 +1.5% ·
PALI
Palisade Bio
 Jul 06, 2026 BUY Strong Buy
+1159.8% avg upside
16 analysts
$5.00
138.19% Upside
 +4.9% ·
APGE
Apogee Therapeutics
 Jun 29, 2026 BUY Buy
-5.5% avg upside
19 analysts
$133.00
1.42% Downside
 +1.6% ·
ORKA
Oruka Therapeutics
 Jun 29, 2026 BUY Strong Buy
+12.4% avg upside
16 analysts
$150.00
30.41% Upside
 +18.6% ·
EQ
Equillium
 May 28, 2026 BUY Strong Buy
+297.1% avg upside
16 analysts
$5.00
109.14% Upside
 -16.9% ·
AVTX
Avalo Therapeutics
 May 15, 2026 BUY Strong Buy
+163.1% avg upside
20 analysts
$39.00
97.81% Upside
 +10.4% ·
ASND
Ascendis Pharma
 May 08, 2026 BUY Strong Buy
+10.5% avg upside
24 analysts
$328.00
22.25% Upside
 +4.1% ·
ACRS
Aclaris Therapeutics
 May 08, 2026 HOLD Strong Buy
+61.1% avg upside
15 analysts
$4.00
36.54% Downside
 +20.1% ·
ANAB
AnaptysBio
 Mar 05, 2026 BUY Strong Buy
+22.5% avg upside
26 analysts
$85.00
40.96% Upside
 +53.1% ·
MLTX
MoonLake Immunotherapeutics
 Mar 01, 2026 HOLD Buy
+80.6% avg upside
20 analysts
$19.00
15.29% Upside
 -6.8% ·
PLRX
Pliant Therapeutics
 Mar 03, 2025 HOLD Buy
+1826.1% avg upside
21 analysts
$3.00
160.87% Upside
 -9.4% ·
HLIT
Harmonic
 Nov 07, 2024 BUY Buy
+3.4% avg upside
14 analysts
$23.00
78.73% Upside
 -16.2% ·
APOG
Apogee
 Aug 08, 2023 BUY Strong Buy
+9.1% avg upside
7 analysts
$34.00
19.13% Downside
 +25.8% ·
🔒 21 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Alex Thompson CFA — Frequently Asked Questions
How accurate are Alex Thompson CFA's stock ratings?
Based on the calls 13Foresight could measure, about 71% of Alex's ratings were profitable over a one-year hold, with an average return of +12.0% per rating, or +37.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Alex ranked on 13Foresight?
Alex Thompson CFA is currently ranked #575 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Alex cover?
Alex most recently has ratings on SEPN, ALMS, JBIO, CGEM, KYMR, DNTH, VRDN, SYRE, EVMN, IMVT, TVTX, ARGX and 14 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.